NCT02037191View on ClinicalTrials.gov

The Efficiency Of The Methotrexate At Patients Affected By Grave Pelade

PHASE3CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
ALOPECIA AREATA
Interventions
DRUG

Methotrexate

"Non responder patients in arm A will be re-randomized to receive from month 6 to the end of the study (month 12):~methotrexate alone or methotrexate associated with prednisone 0.3 mg/Kg/day"

DRUG

Placebo

"Non responder patients in arm B will be re-randomized to receive from month 6 to the end of the study (month 12):~methotrexate alone or methotrexate associated with prednisone 0.3 mg/Kg/day"

Trial Locations (2)

76031

Head Dermatology Department, Rouen

CHU de Rouen - Hôpitaux de Rouen, Rouen

All Listed Sponsors
lead

University Hospital, Rouen

OTHER

NCT02037191 - The Efficiency Of The Methotrexate At Patients Affected By Grave Pelade | Biotech Hunter | Biotech Hunter